Effect of Bevacizumab Combined with XELOX Chemotherapy Regimen in the Treatment of Elderly Patients with Advanced Colorectal Cancer
Objective:To analyze the effect of bevacizumab combined with XELOX chemotherapy regimen on elderly patients with advanced colorectal cancer. Methods:A total of 92 elderly patients with advanced colorectal cancer admitted to Hubei Wuxue First People's Hospital from January 2021 to January 2023 were selected and divided into two groups according to the random number table method,with 46 patients in each group. The control group was treated with XELOX chemotherapy regimen,and the observation group was treated with bevacizumab. The clinical efficacy,immune function,tumor marker level,quality of life and adverse reactions were compared between the two groups. Results:The total effective rate of treatment in the observation group was 78.26％,which was higher than 54.35％ in the control group (P<0.05). After treatment,the scores of CD3+,CD4+and WHOQOL-BREF in the observation group were higher than those in the control group,and the levels of CD8+and tumor markers were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:Bevacizumab combined with XELOX chemotherapy can improve the immune function of elderly patients with advanced colorectal cancer,reduce the level of tumor markers,improve the quality of life,and have no serious adverse reactions,which has certain application value.
Advanced colorectal cancerBevacizumabImmune functionQuality of lifeAdverse reactions
万方数据
维普
